Open Access. Powered by Scholars. Published by Universities.®
Cell and Developmental Biology Commons™
Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 2 of 2
Full-Text Articles in Cell and Developmental Biology
Evaluation Of Eltrombopag In Thrombocytopenia Post Hematopoietic Cell Transplantation, H Samarkandi, M Al Nahedh, A Alfattani, F Alsharif, N Bakshi, W Rasheed, F Alfraih, M Alhumaid, Nora Alkhudair, S Alhayli, H Alsaedi, M Shaheen, A Hanbali, S.K. Hashmi, E Devol, A Alseraihy, H Alzahrani, M Aljurf
Evaluation Of Eltrombopag In Thrombocytopenia Post Hematopoietic Cell Transplantation, H Samarkandi, M Al Nahedh, A Alfattani, F Alsharif, N Bakshi, W Rasheed, F Alfraih, M Alhumaid, Nora Alkhudair, S Alhayli, H Alsaedi, M Shaheen, A Hanbali, S.K. Hashmi, E Devol, A Alseraihy, H Alzahrani, M Aljurf
Hematology/Oncology and Stem Cell Therapy
Background: Thrombocytopenia remains a life-threatening late complication of HCT with an incidence of 5e20%. Currently, there is no approved drug for the treatment of persistent thrombocytopenia post HCT and platelet transfusion is the maintain stay of treatment. Eltrombopag is approved for the treatment of thrombocytopenia associated with different diseases, however; data on eltrombopag treatment post HCT are limited. Methods: This is a retrospective cohort study evaluating the effect of eltrombopag on platelet recovery in patients with persistent thrombocytopenia post HCT. The primary endpoint was platelet recovery to ≥ 20,000/mL for 7 consecutive days without transfusion support after starting eltrombopag. Secondary …
Use Of Thrombopoietin Receptor Agonists In Pregnancy: A Review Of The Literature, Jude Howaidi, Abdullah M. Alrajhi, Ali Howaidi, Fouad H. Alnajjar, Imran K. Tailor
Use Of Thrombopoietin Receptor Agonists In Pregnancy: A Review Of The Literature, Jude Howaidi, Abdullah M. Alrajhi, Ali Howaidi, Fouad H. Alnajjar, Imran K. Tailor
Hematology/Oncology and Stem Cell Therapy
The management of immune thrombocytopenic purpura (ITP) involves several lines of therapy such as corticosteroids and intravenous immunoglobulin. With the emergence of novel therapies such as thrombopoietin receptor agonists (TPO-RAs), there has been a shift in treatment modalities. Eltrombopag and romiplostim have proven to be effective in the management of ITP through clinical studies, but their safety in pregnancy remains uncertain. The purpose of the study is to review the literature to evaluate the safety of TPO-RAs in pregnant women. Ten case reports and a cohort study pertaining to the use of TPO-RAs in pregnancy were obtained. According to the …